Phase II Randomized, Double-blind, Placebo-controlled Study of LEE011(Ribociclib) or Placebo in Combination With Endocrine Therapy for the Treatment of Pre- and Postmenopausal Chinese Women With HR Positive, HER2-negative, Advanced Breast Cancer, Including a Subset With Pharmacokinetic Analysis
Latest Information Update: 22 May 2025
At a glance
- Drugs Anastrozole (Primary) ; Letrozole (Primary) ; Ribociclib (Primary) ; Goserelin
- Indications Advanced breast cancer; HER2 negative breast cancer
- Focus Therapeutic Use
- Sponsors Novartis Pharmaceuticals
Most Recent Events
- 15 May 2025 Status changed from active, no longer recruiting to completed.
- 17 Mar 2025 Planned End Date changed from 16 Jun 2025 to 9 May 2025.
- 01 Oct 2024 Planned End Date changed from 15 Apr 2025 to 16 Jun 2025.